Nigel K Stepto1,2,3,4, Alba Moreno-Asso1,3, Luke C McIlvenna1, Kirsty A Walters5, Raymond J Rodgers6. 1. Institute for Health and Sport, Victoria University, Footscray, Victoria, Australia. 2. Monash Centre for Health Research and Implementation, Monash University and Monash Health, Clayton, Victoria, Australia. 3. Australian Institute of Musculoskeletal Science, Victoria University, St. Albans, Victoria, Australia. 4. Medicine at Western Health, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia. 5. School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia. 6. The Robinson Research Institute, The University of Adelaide, North Adelaide, South Australia, Australia.
Abstract
CONTEXT: Polycystic ovary syndrome (PCOS) is a common endocrine condition affecting 8% to 13% of women across the lifespan. PCOS affects reproductive, metabolic, and mental health, generating a considerable health burden. Advances in treatment of women with PCOS has been hampered by evolving diagnostic criteria and poor recognition by clinicians. This has resulted in limited clinical and basic research. In this study, we provide insights into the current and future research on the metabolic features of PCOS, specifically as they relate to PCOS-specific insulin resistance (IR), that may affect the most metabolically active tissue, skeletal muscle. CURRENT KNOWLEDGE: PCOS is a highly heritable condition, yet it is phenotypically heterogeneous in both reproductive and metabolic features. Human studies thus far have not identified molecular mechanisms of PCOS-specific IR in skeletal muscle. However, recent research has provided new insights that implicate energy-sensing pathways regulated via epigenomic and resultant transcriptomic changes. Animal models, while in existence, have been underused in exploring molecular mechanisms of IR in PCOS and specifically in skeletal muscle. FUTURE DIRECTIONS: Based on the latest evidence synthesis and technologies, researchers exploring molecular mechanisms of IR in PCOS, specifically in muscle, will likely need to generate new hypothesis to be tested in human and animal studies. CONCLUSION: Investigations to elucidate the molecular mechanisms driving IR in PCOS are in their early stages, yet remarkable advances have been made in skeletal muscle. Overall, investigations have thus far created more questions than answers, which provide new opportunities to study complex endocrine conditions.
CONTEXT: Polycystic ovary syndrome (PCOS) is a common endocrine condition affecting 8% to 13% of women across the lifespan. PCOS affects reproductive, metabolic, and mental health, generating a considerable health burden. Advances in treatment of women with PCOS has been hampered by evolving diagnostic criteria and poor recognition by clinicians. This has resulted in limited clinical and basic research. In this study, we provide insights into the current and future research on the metabolic features of PCOS, specifically as they relate to PCOS-specific insulin resistance (IR), that may affect the most metabolically active tissue, skeletal muscle. CURRENT KNOWLEDGE: PCOS is a highly heritable condition, yet it is phenotypically heterogeneous in both reproductive and metabolic features. Human studies thus far have not identified molecular mechanisms of PCOS-specific IR in skeletal muscle. However, recent research has provided new insights that implicate energy-sensing pathways regulated via epigenomic and resultant transcriptomic changes. Animal models, while in existence, have been underused in exploring molecular mechanisms of IR in PCOS and specifically in skeletal muscle. FUTURE DIRECTIONS: Based on the latest evidence synthesis and technologies, researchers exploring molecular mechanisms of IR in PCOS, specifically in muscle, will likely need to generate new hypothesis to be tested in human and animal studies. CONCLUSION: Investigations to elucidate the molecular mechanisms driving IR in PCOS are in their early stages, yet remarkable advances have been made in skeletal muscle. Overall, investigations have thus far created more questions than answers, which provide new opportunities to study complex endocrine conditions.
Authors: Monica D Hartanti; Roseanne Rosario; Katja Hummitzsch; Nicole A Bastian; Nicholas Hatzirodos; Wendy M Bonner; Rosemary A Bayne; Helen F Irving-Rodgers; Richard A Anderson; Raymond J Rodgers Journal: PLoS One Date: 2020-02-20 Impact factor: 3.240
Authors: Elisabet Stener-Victorin; Vasantha Padmanabhan; Kirsty A Walters; Rebecca E Campbell; Anna Benrick; Paolo Giacobini; Daniel A Dumesic; David H Abbott Journal: Endocr Rev Date: 2020-07-01 Impact factor: 19.871
Authors: Maryam Kazemi; Brittany Y Jarrett; Stephen A Parry; Anna E Thalacker-Mercer; Kathleen M Hoeger; Steven D Spandorfer; Marla E Lujan Journal: J Clin Endocrinol Metab Date: 2020-09-01 Impact factor: 5.958
Authors: Rafiatu Azumah; Menghe Liu; Katja Hummitzsch; Nicole A Bastian; Monica D Hartanti; Helen F Irving-Rodgers; Richard A Anderson; Raymond J Rodgers Journal: Hum Reprod Date: 2022-05-30 Impact factor: 6.353
Authors: Danielle Hiam; Alba Moreno-Asso; Helena J Teede; Joop S E Laven; Nigel K Stepto; Lisa J Moran; Melanie Gibson-Helm Journal: J Clin Med Date: 2019-10-03 Impact factor: 4.241